nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—CHRM3—ureter—urinary bladder cancer	0.241	0.402	CbGeAlD
Mepenzolate—CHRM3—muscle of abdomen—urinary bladder cancer	0.174	0.29	CbGeAlD
Mepenzolate—Ageusia—Valrubicin—urinary bladder cancer	0.0351	0.0878	CcSEcCtD
Mepenzolate—CHRM2—prostate gland—urinary bladder cancer	0.0346	0.0576	CbGeAlD
Mepenzolate—CHRM1—prostate gland—urinary bladder cancer	0.0315	0.0525	CbGeAlD
Mepenzolate—CHRM3—prostate gland—urinary bladder cancer	0.0282	0.0469	CbGeAlD
Mepenzolate—CHRM3—smooth muscle tissue—urinary bladder cancer	0.0199	0.0332	CbGeAlD
Mepenzolate—Urinary retention—Valrubicin—urinary bladder cancer	0.0196	0.0491	CcSEcCtD
Mepenzolate—CHRM3—renal system—urinary bladder cancer	0.0192	0.032	CbGeAlD
Mepenzolate—CHRM3—urethra—urinary bladder cancer	0.0188	0.0314	CbGeAlD
Mepenzolate—CHRM1—female reproductive system—urinary bladder cancer	0.0172	0.0286	CbGeAlD
Mepenzolate—CHRM3—female reproductive system—urinary bladder cancer	0.0154	0.0256	CbGeAlD
Mepenzolate—Drowsiness—Mitomycin—urinary bladder cancer	0.011	0.0274	CcSEcCtD
Mepenzolate—Ageusia—Cisplatin—urinary bladder cancer	0.00954	0.0238	CcSEcCtD
Mepenzolate—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00837	0.0209	CcSEcCtD
Mepenzolate—Vision blurred—Mitomycin—urinary bladder cancer	0.00808	0.0202	CcSEcCtD
Mepenzolate—Asthenia—Valrubicin—urinary bladder cancer	0.00728	0.0182	CcSEcCtD
Mepenzolate—Confusional state—Mitomycin—urinary bladder cancer	0.00705	0.0176	CcSEcCtD
Mepenzolate—Urinary retention—Thiotepa—urinary bladder cancer	0.0068	0.017	CcSEcCtD
Mepenzolate—Dizziness—Valrubicin—urinary bladder cancer	0.00671	0.0168	CcSEcCtD
Mepenzolate—Vomiting—Valrubicin—urinary bladder cancer	0.00645	0.0161	CcSEcCtD
Mepenzolate—Headache—Valrubicin—urinary bladder cancer	0.00636	0.0159	CcSEcCtD
Mepenzolate—Somnolence—Mitomycin—urinary bladder cancer	0.00622	0.0155	CcSEcCtD
Mepenzolate—Nausea—Valrubicin—urinary bladder cancer	0.00603	0.0151	CcSEcCtD
Mepenzolate—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00576	0.0144	CcSEcCtD
Mepenzolate—Asthenia—Mitomycin—urinary bladder cancer	0.00502	0.0125	CcSEcCtD
Mepenzolate—Ageusia—Epirubicin—urinary bladder cancer	0.0049	0.0122	CcSEcCtD
Mepenzolate—Dizziness—Mitomycin—urinary bladder cancer	0.00462	0.0116	CcSEcCtD
Mepenzolate—Ageusia—Doxorubicin—urinary bladder cancer	0.00453	0.0113	CcSEcCtD
Mepenzolate—Vomiting—Mitomycin—urinary bladder cancer	0.00445	0.0111	CcSEcCtD
Mepenzolate—Headache—Mitomycin—urinary bladder cancer	0.00438	0.0109	CcSEcCtD
Mepenzolate—Tension—Thiotepa—urinary bladder cancer	0.00423	0.0106	CcSEcCtD
Mepenzolate—Nervousness—Thiotepa—urinary bladder cancer	0.00419	0.0105	CcSEcCtD
Mepenzolate—Nausea—Mitomycin—urinary bladder cancer	0.00415	0.0104	CcSEcCtD
Mepenzolate—Vision blurred—Thiotepa—urinary bladder cancer	0.00406	0.0101	CcSEcCtD
Mepenzolate—Confusional state—Thiotepa—urinary bladder cancer	0.00355	0.00886	CcSEcCtD
Mepenzolate—Tachycardia—Thiotepa—urinary bladder cancer	0.00343	0.00858	CcSEcCtD
Mepenzolate—Vision blurred—Fluorouracil—urinary bladder cancer	0.00336	0.00839	CcSEcCtD
Mepenzolate—Vision blurred—Cisplatin—urinary bladder cancer	0.00318	0.00796	CcSEcCtD
Mepenzolate—Somnolence—Thiotepa—urinary bladder cancer	0.00313	0.00781	CcSEcCtD
Mepenzolate—Constipation—Thiotepa—urinary bladder cancer	0.00301	0.00752	CcSEcCtD
Mepenzolate—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00296	0.00739	CcSEcCtD
Mepenzolate—Confusional state—Fluorouracil—urinary bladder cancer	0.00293	0.00733	CcSEcCtD
Mepenzolate—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00291	0.00727	CcSEcCtD
Mepenzolate—Feeling abnormal—Thiotepa—urinary bladder cancer	0.0029	0.00724	CcSEcCtD
Mepenzolate—Tachycardia—Fluorouracil—urinary bladder cancer	0.00284	0.00709	CcSEcCtD
Mepenzolate—Urticaria—Thiotepa—urinary bladder cancer	0.00279	0.00698	CcSEcCtD
Mepenzolate—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00276	0.00689	CcSEcCtD
Mepenzolate—Tachycardia—Cisplatin—urinary bladder cancer	0.00269	0.00672	CcSEcCtD
Mepenzolate—Insomnia—Gemcitabine—urinary bladder cancer	0.00268	0.00669	CcSEcCtD
Mepenzolate—Insomnia—Fluorouracil—urinary bladder cancer	0.00263	0.00657	CcSEcCtD
Mepenzolate—Somnolence—Gemcitabine—urinary bladder cancer	0.00263	0.00657	CcSEcCtD
Mepenzolate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00259	0.00647	CcSEcCtD
Mepenzolate—Somnolence—Fluorouracil—urinary bladder cancer	0.00259	0.00646	CcSEcCtD
Mepenzolate—Confusional state—Etoposide—urinary bladder cancer	0.00255	0.00637	CcSEcCtD
Mepenzolate—Constipation—Gemcitabine—urinary bladder cancer	0.00253	0.00632	CcSEcCtD
Mepenzolate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00253	0.00631	CcSEcCtD
Mepenzolate—Asthenia—Thiotepa—urinary bladder cancer	0.00252	0.00631	CcSEcCtD
Mepenzolate—Abdominal distension—Epirubicin—urinary bladder cancer	0.00251	0.00626	CcSEcCtD
Mepenzolate—Tachycardia—Etoposide—urinary bladder cancer	0.00247	0.00616	CcSEcCtD
Mepenzolate—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00245	0.00612	CcSEcCtD
Mepenzolate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00244	0.00609	CcSEcCtD
Mepenzolate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.0024	0.00599	CcSEcCtD
Mepenzolate—Drowsiness—Methotrexate—urinary bladder cancer	0.00237	0.00593	CcSEcCtD
Mepenzolate—Dizziness—Thiotepa—urinary bladder cancer	0.00233	0.00581	CcSEcCtD
Mepenzolate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00232	0.0058	CcSEcCtD
Mepenzolate—Urticaria—Fluorouracil—urinary bladder cancer	0.00231	0.00577	CcSEcCtD
Mepenzolate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00227	0.00568	CcSEcCtD
Mepenzolate—Somnolence—Etoposide—urinary bladder cancer	0.00225	0.00561	CcSEcCtD
Mepenzolate—Vomiting—Thiotepa—urinary bladder cancer	0.00224	0.00559	CcSEcCtD
Mepenzolate—Drowsiness—Epirubicin—urinary bladder cancer	0.00222	0.00555	CcSEcCtD
Mepenzolate—Headache—Thiotepa—urinary bladder cancer	0.0022	0.00551	CcSEcCtD
Mepenzolate—Constipation—Etoposide—urinary bladder cancer	0.00216	0.0054	CcSEcCtD
Mepenzolate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00214	0.00536	CcSEcCtD
Mepenzolate—Asthenia—Gemcitabine—urinary bladder cancer	0.00212	0.0053	CcSEcCtD
Mepenzolate—Nausea—Thiotepa—urinary bladder cancer	0.00209	0.00522	CcSEcCtD
Mepenzolate—Feeling abnormal—Etoposide—urinary bladder cancer	0.00208	0.0052	CcSEcCtD
Mepenzolate—Drowsiness—Doxorubicin—urinary bladder cancer	0.00205	0.00513	CcSEcCtD
Mepenzolate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00203	0.00508	CcSEcCtD
Mepenzolate—Urticaria—Etoposide—urinary bladder cancer	0.00201	0.00501	CcSEcCtD
Mepenzolate—Asthenia—Cisplatin—urinary bladder cancer	0.00198	0.00494	CcSEcCtD
Mepenzolate—Dizziness—Fluorouracil—urinary bladder cancer	0.00192	0.00481	CcSEcCtD
Mepenzolate—Vomiting—Gemcitabine—urinary bladder cancer	0.00188	0.0047	CcSEcCtD
Mepenzolate—Hypersensitivity—Etoposide—urinary bladder cancer	0.00186	0.00465	CcSEcCtD
Mepenzolate—Headache—Gemcitabine—urinary bladder cancer	0.00185	0.00463	CcSEcCtD
Mepenzolate—Vomiting—Fluorouracil—urinary bladder cancer	0.00185	0.00462	CcSEcCtD
Mepenzolate—Headache—Fluorouracil—urinary bladder cancer	0.00182	0.00455	CcSEcCtD
Mepenzolate—Asthenia—Etoposide—urinary bladder cancer	0.00181	0.00453	CcSEcCtD
Mepenzolate—Nausea—Gemcitabine—urinary bladder cancer	0.00176	0.00439	CcSEcCtD
Mepenzolate—Vomiting—Cisplatin—urinary bladder cancer	0.00175	0.00438	CcSEcCtD
Mepenzolate—Vision blurred—Methotrexate—urinary bladder cancer	0.00175	0.00437	CcSEcCtD
Mepenzolate—Nausea—Fluorouracil—urinary bladder cancer	0.00173	0.00432	CcSEcCtD
Mepenzolate—Tension—Epirubicin—urinary bladder cancer	0.0017	0.00425	CcSEcCtD
Mepenzolate—Nervousness—Epirubicin—urinary bladder cancer	0.00169	0.00421	CcSEcCtD
Mepenzolate—Dizziness—Etoposide—urinary bladder cancer	0.00167	0.00417	CcSEcCtD
Mepenzolate—Nausea—Cisplatin—urinary bladder cancer	0.00164	0.00409	CcSEcCtD
Mepenzolate—Vision blurred—Epirubicin—urinary bladder cancer	0.00164	0.00409	CcSEcCtD
Mepenzolate—Vomiting—Etoposide—urinary bladder cancer	0.00161	0.00401	CcSEcCtD
Mepenzolate—Headache—Etoposide—urinary bladder cancer	0.00158	0.00395	CcSEcCtD
Mepenzolate—Tension—Doxorubicin—urinary bladder cancer	0.00158	0.00394	CcSEcCtD
Mepenzolate—Nervousness—Doxorubicin—urinary bladder cancer	0.00156	0.0039	CcSEcCtD
Mepenzolate—Palpitations—Epirubicin—urinary bladder cancer	0.00153	0.00383	CcSEcCtD
Mepenzolate—Confusional state—Methotrexate—urinary bladder cancer	0.00153	0.00381	CcSEcCtD
Mepenzolate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00151	0.00378	CcSEcCtD
Mepenzolate—Vision blurred—Doxorubicin—urinary bladder cancer	0.00151	0.00378	CcSEcCtD
Mepenzolate—Nausea—Etoposide—urinary bladder cancer	0.0015	0.00375	CcSEcCtD
Mepenzolate—Dry mouth—Epirubicin—urinary bladder cancer	0.00144	0.00361	CcSEcCtD
Mepenzolate—Confusional state—Epirubicin—urinary bladder cancer	0.00143	0.00357	CcSEcCtD
Mepenzolate—Palpitations—Doxorubicin—urinary bladder cancer	0.00142	0.00355	CcSEcCtD
Mepenzolate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00142	0.00354	CcSEcCtD
Mepenzolate—Tachycardia—Epirubicin—urinary bladder cancer	0.00138	0.00345	CcSEcCtD
Mepenzolate—Insomnia—Methotrexate—urinary bladder cancer	0.00137	0.00342	CcSEcCtD
Mepenzolate—Somnolence—Methotrexate—urinary bladder cancer	0.00135	0.00336	CcSEcCtD
Mepenzolate—Dry mouth—Doxorubicin—urinary bladder cancer	0.00134	0.00334	CcSEcCtD
Mepenzolate—Confusional state—Doxorubicin—urinary bladder cancer	0.00132	0.0033	CcSEcCtD
Mepenzolate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00131	0.00327	CcSEcCtD
Mepenzolate—Insomnia—Epirubicin—urinary bladder cancer	0.00128	0.0032	CcSEcCtD
Mepenzolate—Tachycardia—Doxorubicin—urinary bladder cancer	0.00128	0.0032	CcSEcCtD
Mepenzolate—Somnolence—Epirubicin—urinary bladder cancer	0.00126	0.00315	CcSEcCtD
Mepenzolate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00125	0.00312	CcSEcCtD
Mepenzolate—Constipation—Epirubicin—urinary bladder cancer	0.00121	0.00303	CcSEcCtD
Mepenzolate—Urticaria—Methotrexate—urinary bladder cancer	0.0012	0.003	CcSEcCtD
Mepenzolate—Insomnia—Doxorubicin—urinary bladder cancer	0.00119	0.00296	CcSEcCtD
Mepenzolate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00117	0.00292	CcSEcCtD
Mepenzolate—Somnolence—Doxorubicin—urinary bladder cancer	0.00116	0.00291	CcSEcCtD
Mepenzolate—Urticaria—Epirubicin—urinary bladder cancer	0.00113	0.00281	CcSEcCtD
Mepenzolate—Constipation—Doxorubicin—urinary bladder cancer	0.00112	0.0028	CcSEcCtD
Mepenzolate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00111	0.00279	CcSEcCtD
Mepenzolate—Asthenia—Methotrexate—urinary bladder cancer	0.00109	0.00271	CcSEcCtD
Mepenzolate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00108	0.0027	CcSEcCtD
Mepenzolate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00104	0.00261	CcSEcCtD
Mepenzolate—Urticaria—Doxorubicin—urinary bladder cancer	0.00104	0.0026	CcSEcCtD
Mepenzolate—Asthenia—Epirubicin—urinary bladder cancer	0.00102	0.00254	CcSEcCtD
Mepenzolate—Dizziness—Methotrexate—urinary bladder cancer	0.001	0.0025	CcSEcCtD
Mepenzolate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000965	0.00241	CcSEcCtD
Mepenzolate—Vomiting—Methotrexate—urinary bladder cancer	0.000962	0.0024	CcSEcCtD
Mepenzolate—Headache—Methotrexate—urinary bladder cancer	0.000948	0.00237	CcSEcCtD
Mepenzolate—Asthenia—Doxorubicin—urinary bladder cancer	0.00094	0.00235	CcSEcCtD
Mepenzolate—Dizziness—Epirubicin—urinary bladder cancer	0.000936	0.00234	CcSEcCtD
Mepenzolate—Vomiting—Epirubicin—urinary bladder cancer	0.0009	0.00225	CcSEcCtD
Mepenzolate—Nausea—Methotrexate—urinary bladder cancer	0.000899	0.00225	CcSEcCtD
Mepenzolate—Headache—Epirubicin—urinary bladder cancer	0.000887	0.00222	CcSEcCtD
Mepenzolate—Dizziness—Doxorubicin—urinary bladder cancer	0.000867	0.00217	CcSEcCtD
Mepenzolate—Nausea—Epirubicin—urinary bladder cancer	0.000841	0.0021	CcSEcCtD
Mepenzolate—Vomiting—Doxorubicin—urinary bladder cancer	0.000833	0.00208	CcSEcCtD
Mepenzolate—Headache—Doxorubicin—urinary bladder cancer	0.000821	0.00205	CcSEcCtD
Mepenzolate—Nausea—Doxorubicin—urinary bladder cancer	0.000778	0.00194	CcSEcCtD
